ZYBERNO
Stock Report
Updated Aug 21, 2026

Alector, Inc. (ALEC)

Healthcare • NASDAQ

$2.29

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
17.0/100
POOR BUSINESS
Alector, Inc. (ALEC) scores 17/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-531.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-914.1%)
Return on Capital (Capital Efficiency):CRITICAL (-66.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Alector, Inc. (ALEC) stock report — Zyberno Score 17/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ALEC generated -$173.20M in Owner Earnings. Capital was deployed as follows: $139.00K invested in capital expenditures. Reinvestment rate: 6.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.29
Market Cap:$254.70M

Valuation Multiples (2)

P/S Ratio:18.41x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$218.34M

Price Action & Momentum (1)

% of 52-Week High:67.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-44.0%
Reinvestment Rate:6.0%
Fundamental Growth Rate (g):-4.0%

Margin Analysis (3)

Operating Margin Ttm:-914.1%
Net Margin Ttm:-851.7%
Ebitda Margin:-872.1%

TTM Performance (2)

Operating Margin Ttm:-914.1%
Net Margin Ttm:-851.7%

Yield Metrics (2)

Earnings Yield:-$53.92
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:39.5%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-38.5%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:5.26x
Quick Ratio:5.26x
Cash Ratio:1.75x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:145,851,000.00
Cash And Cash Equivalents:59,915,000.00
Long Term Debt:$13.70M
Net Debt:-$36.37M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $13.84M
Linear Growth: -38.5%
📊 Click to view full ALEC Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$126.49M

Bottom Line Performance (3)

-$117.85M
Income Before Tax:-$117.53M
Ebitda Ttm:-120,671,000.00

Operating Expenses (5)

Operating Expenses:140,349,000.00
R And D Expense:99,130,000.00
Sga Expense:41,219,000.00
Income Tax Expense:$298.00K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:2,985.8%
Sga To Revenue Percentage:1,241.5%
Ebitda Margin:-872.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$202.86M
Current Assets:$180.09M
Ppe Net:8,912,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:212,825,000.00
Current Liabilities:34,236,000.00
Long Term Debt:$13.70M
Short Term Debt:$9.85M

Equity & Capital (3)

Equity:-$9.97M
Retained Earnings:-$1.02B
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:7,036,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,610,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$173.06M-$173.20M

Investment Activities (2)

Investing Cash Flow:$60.95M
Capital Expenditures Ttm:139,000.00

Financing Activities (3)

Financing Cash Flow:$25.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:19,983,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:5,815,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.10
-$1.10
Earnings Per Share Ttm:-$1.06

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.12
Operating Cash Flow Per Share:-$1.65

Book Value & Capital (2)

Book Value Per Share:-$0.09
Cash Per Share:0.54

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.05x
Working Capital Turnover Ttm:0.09x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:185.60
Cash Conversion Cycle:-2,183.60
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$173.20M

Damodaran Growth Analysis (2)

Reinvestment Rate:6.0%
Fundamental Growth Rate (g):-4.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-38.5%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-45.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:ALEC
Company Name:Alector, Inc.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:111.22M
Shares Outstanding Basic:111.22M
Shares Outstanding Diluted:111.22M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-21 17:49:50 UTC
Data Timestamp:2026-08-19T00:36:04.224134
Scroll to Top